These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25954797)

  • 1. Interferon alfa: hyperpigmentation.
    Prescrire Int; 2014 Nov; 23(154):268. PubMed ID: 25954797
    [No Abstract]   [Full Text] [Related]  

  • 2. Tongue hyperpigmentation during PEG-interferon-alfa/ribavirin therapy in a non-Caucasian patient with chronic hepatitis C: a case report and review of the literature.
    Mlika RB; Kerkeni N; Marrak H; Fenniche S; Mokhtar I; Debbiche A
    Int J Dermatol; 2013 May; 52(5):643-4. PubMed ID: 23046405
    [No Abstract]   [Full Text] [Related]  

  • 3. Iatrogenic hyperpigmentation in chronically infected hepatitis C patients treated with pegylated interferon and ribavirin.
    Lin J; Lott JP; Amorosa VK; Kovarik CL
    J Am Acad Dermatol; 2009 May; 60(5):882-3. PubMed ID: 19389538
    [No Abstract]   [Full Text] [Related]  

  • 4. What caused this lingual hyperpigmentation in a patient with chronic hepatitis C?
    Radha Krishna Y; Itha S
    Liver Int; 2010 Mar; 30(3):416. PubMed ID: 19422481
    [No Abstract]   [Full Text] [Related]  

  • 5. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
    Tsilika K; Tran A; Trucchi R; Pop S; Anty R; Cardot-Leccia N; Lacour JP; Ortonne JP; Passeron T
    JAMA Dermatol; 2013 Jun; 149(6):675-7. PubMed ID: 23553009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A surprising hyperpigmentation of the gums and tongue.
    Dell'Isola S; Ialungo AM; Starnini G; Roselli P; Ghittoni G; Caturelli E
    Gut; 2008 Dec; 57(12):1697, 1727. PubMed ID: 19022927
    [No Abstract]   [Full Text] [Related]  

  • 7. Erythema gyratum repens induced by pegylated interferon alfa for chronic hepatitis C.
    Rongioletti F; Fausti V; Parodi A
    Arch Dermatol; 2012 Oct; 148(10):1213-4. PubMed ID: 23069974
    [No Abstract]   [Full Text] [Related]  

  • 8. A rare complication of pegylated interferon Alfa 2a in a hepatitis C-positive patient on maintenance hemodialysis.
    Satish R; ; Mathew T
    Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):139-42. PubMed ID: 22237239
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
    Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
    Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
    [No Abstract]   [Full Text] [Related]  

  • 10. [Secondary hemophagocytic syndrome due to Peg-interferon administration].
    Ruiz Ramos J
    Farm Hosp; 2014 Jan; 38(1):73-4. PubMed ID: 24483865
    [No Abstract]   [Full Text] [Related]  

  • 11. Pegylated interferon associated lichen planus at the injection site.
    Ergül B; Koçak E; Akbal E; Köklü S; Astarci HM
    Acta Gastroenterol Belg; 2011 Dec; 74(4):591-2. PubMed ID: 22319976
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFNα2b.
    Chung E; Park K; Kim JH; Han NI; Lee YS; Bae SH; Park CH
    Korean J Intern Med; 2017 Nov; 32(6):1098-1100. PubMed ID: 28823117
    [No Abstract]   [Full Text] [Related]  

  • 13. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
    Iwasaki Y; Ikeda F; Yamamoto K
    Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J; Afridi MS
    Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection.
    Bachmeyer C; Moguelet P; Gombeaud T; Sbidian E; Aractingi S
    Arch Dermatol; 2011 Oct; 147(10):1232-3. PubMed ID: 22006152
    [No Abstract]   [Full Text] [Related]  

  • 16. Tongue hyperpigmentation during interferon therapy.
    Karabay O; Goksugur N; Ogutlu A
    J Dermatol; 2011 Mar; 38(3):290-1. PubMed ID: 21342236
    [No Abstract]   [Full Text] [Related]  

  • 17. Facial hyperpigmentation during pegylated interferon alpha therapy for chronic hepatitis B infection.
    Dag MS; Aydinli M; Kazanci U; Kadayifci A
    Acta Gastroenterol Belg; 2011 Mar; 74(1):103-4. PubMed ID: 21563666
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute life-threatening event with peginterferon α-2b in a child with chronic hepatitis C.
    Bhat AS; Varma S; Chaturvedi MK
    J Pediatr Gastroenterol Nutr; 2012 Nov; 55(5):e138. PubMed ID: 22847460
    [No Abstract]   [Full Text] [Related]  

  • 19. Thrombotic microangiopathy complicating pegylated interferon treatment of hepatitis C infection.
    Iskander D; Wickremasinghe M; Bain BJ
    Am J Hematol; 2011 Oct; 86(10):859. PubMed ID: 21630311
    [No Abstract]   [Full Text] [Related]  

  • 20. Peripheral nervous system involvement in a haemodialysis patient treated with pegylated interferon.
    Ruiz-Fuentes MC; Rubert-Gómez De Quero A; De Gracia-Guindo C; Galindo-Sacristán P; Osuna-Ortega A
    Nefrologia; 2012; 32(6):863-5. PubMed ID: 23169385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.